In contrast to melanoma non-responders, responders to immune checkpoint inhibitors had higher baseline tumor infiltration by CD8+ and PD-1+ T cells associated with PD-L1 upregulation in close tumor vicinity [25]. This evidence concerns the gene PDCD1 and neoplasm.